[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Subscription::
Contact us::
Site Facilities::
::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Last site contents
:: Editorial Board
:: About Iranian Journal of Endocrinology and Metabolism
:: Volume 2, Issue 1 (3-2000) ::
2000, 2(1): 11-17 Back to browse issues page
Comparison of the effect of an Iranian brand of Simvastatin (Simvastatin, Shahre Daroo) with a foreign brand, Zocor
P Heydarian , J Ghanbili , H Emami , F Azizi
Abstract:   (25707 Views)
Abstract: To compare the effects of two brands of Simvastatin, Simvastatin (Shahre Daroo) and Zocor (Merck Sharp & Dohme), 20 hyperlipidemic patients (14 women, 6 men) with a mean age of 53.9±9.4 years, being candidates for drug therapy based on National Cholesterol Education Program guidelines and having no contraindications for using “statin”, were randomly assigned to treatment with Simvastatin (11 patients) or Zocor (9 patients), 20 mg to be taken before the evening meal. The mean basal total cholesterol and LDL cholesterol of patients were 326±38 mg/dl and 245±47 mg/dl, respectively. The patients were visited 4 and 8 weeks after treatment to repeat clinical and laboratory exams. There were no significant differences between the treatment groups in the male to female ratio, mean age, mean basal lipid levels and attending follow up. Four weeks after treatment, Simvastatin reduced total cholesterol by 24.9% ± 4.8 (83 ± 54 mg/dl, P<0.001) and Zocor reduced it by 24.9% ± 3.8 (81 ± 38 mg/dl, P<0.001). Almost all of the difference in total cholesterol at 4 weeks was due to the reduction in LDL cholesterol, 34.2% ± 5.5 (85 ± 47 mg/dl, P<0.001) and 32% ± 4.8 (79 ± 39 mg/dl, P<0.001) in the Simvastatin and Zocor groups respectively. Eight weeks after treatment, Simvastatin reduced total cholesterol by 26.8% ± 4.3 (87 ± 39 mg/dl, P<0.01) and Zocor reduced it by 24.4% ± 3.3 (77 ± 28 mg/dl, P<0.01). Almost all of the difference in total cholesterol at 8 weeks was due to the reduction in LDL cholesterol, 34.6% ± 4.3 (82 ± 29 mg/dl, P<0.001) and 27.8% ± 6.5 (65 ± 42 mg/dl, P<0.05) in the Simvastatin and Zocor groups respectively. Changes in HDL cholesterol and triglycerides were not significant after 4 and 8 weeks of treatment in any group. There were no significant differences between the treatment groups in the changes of any lipid levels. This study shows that Simvastatin (Shahre Daroo) produces similar reductions in total cholesterol and LDL cholesterol as Zocor.
Keywords: Hyperlipidemia, Hyper cholesterolemia, Lipid-lowering drugs, Simvastatin
Full-Text [PDF 313 kb]   (6476 Downloads)    
Type of Study: Original | Subject: Endocrinology
Received: 2006/11/14 | Published: 2000/03/15
Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Heydarian P, Ghanbili J, Emami H, Azizi F. Comparison of the effect of an Iranian brand of Simvastatin (Simvastatin, Shahre Daroo) with a foreign brand, Zocor. Iranian Journal of Endocrinology and Metabolism 2000; 2 (1) :11-17
URL: http://ijem.sbmu.ac.ir/article-1-70-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 2, Issue 1 (3-2000) Back to browse issues page
مجله ی غدد درون‌ریز و متابولیسم ایران، دو ماهنامه  پژوهشی مرکز تحقیقات غدد درون‌ریز و متابولیسم، Iranian Journal of Endocrinology and Metabolism
Persian site map - English site map - Created in 0.05 seconds with 38 queries by YEKTAWEB 4657